Insulin-like growth factor i signaling in skeletal muscle and the potential for cytokine interactions

Medicine and Science in Sports and Exercise

Volumn 42, Issue 1, 2010, Pages 50-57

  Adams, Gregory R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anabolism; ERK; Il 1 ; IL 6; IRS 1; Mtor; TNF

Indexed keywords

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CYTOKINES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUSCLE, SKELETAL; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION;

EID: 73449131158     PISSN: 01959131     EISSN: 15300315     Source Type: Journal    
DOI: 10.1249/MSS.0b013e3181b07d12     Document Type: Review

References (78)

1. Adams GR. Role of IGF-I in the regulation of skeletal muscle adaptation. Exerc Sport Sci Rev. 1998;26:31-60.
2. Adams GR. Invited review: autocrine/paracrine IGF-I and skeletal muscle adaptation. J Appl Physiol. 2002;93:1159-1167
3. Adams GR. Satellite cell proliferation and skeletal muscle hypertrophy. Appl Physiol Nutr Metab. 2006;31:782-790
4. Adams GR, McCue SA. Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J Appl Physiol. 1998;84:1716-1722
5. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem. 2000;275:9047-9054
6. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol. 2002;2:410-416
7. Allen DL, Roy RR, Edgerton VR. Myonuclear domains in muscle adaptation and disease. Muscle Nerve. 1999;22:1350-1360
8. Ballinger A. Fundamental mechanisms of growth failure in inflammatory bowel disease. Horm Res. 2002;58:7-10.
9. Bartoccioni E, Michaelis D, Hohlfeld R. Constitutive and cytokine-induced production of interleukin-6 by human myo-blasts. Immunol Lett. 1994;42:135-138
10. Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Nat Acad Sci U S A. 1998;95:15603-15607
11. Barton-Davis ER, Shoturma DI, Sweeney HL. Contribution of satellite cells to IGF-I induced hypertrophy of skeletal muscle. Acta Physiol Scand. 1999;167:301-305
12. Bodell PW, Kodesh E, Haddad F, Zaldivar FP, Cooper DM, Adams GR. Skeletal muscle growth in young rats is inhibited by chronic exposure to IL-6 but preserved by concurrent voluntary endurance exercise. J Appl Physiol. 106:443-530.
13. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem. 2002;277:23977-23980
14. Bolster DR, Jefferson LS, Kimball SR. Regulation of protein synthesis associated with skeletal muscle hypertrophy by insulin-, amino acid-and exercise-induced signalling. Proc Nutr Soc. 2004; 63:351-356
15. Broussard SR, McCusker RH, Novakofski JE, et al. IL-1A impairs insulin-like growth factor I-induced differentiation and downstream activation signals of the insulin-like growth factor I receptor in myoblasts. J Immunol. 2004;172:7713-7720
16. Cantini M, Massimino ML, Rapizzi E, et al. Human satellite cell proliferation in vitro is regulated by autocrine secretion of IL-6 stimulated by a soluble factor(s) released by activated monocytes. Biochem Biophys Res Commun. 1995;216:49-53.
17. Carey AL, Steinberg GR, Macaulay SL, et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes. 2006;55:2688-2697
18. Cheek DB, Holt AB, Hill DE, Talbert JL. Skeletal muscle mass and growth: the concept of the deoxyribonucleic acid unit. Pediatr Res. 1971;5:312-328
19. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996;271:736-741
20. de Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor < produces insulin resistance in skeletal muscle by activation of inhibitor JB kinase in a p38 MAPK-dependent manner. J Biol Chem. 2004;279:17070-17078
21. de Falco G, Comes F, Simone C. pRb: master of differentiation. Coupling irreversible cell cycle withdrawal with induction of muscle-specific transcription. Oncogene. 2006;25:5244-5249
22. DeBenedetti F, Alonzi T, Moretta A, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-1. A model for stunted growth in children with chronic inflammation. J Clin Invest. 1997;99: 643-650
23. DeBenedetti F, Meazza C, Oliveri M, et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology. 2001; 142:4818-4826
24. Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK. Serum IL-1A, IL-2, and IL-6 in insulin-dependent diabetic children. Mediators Inflamm. 2006;59206:1-6.
25. Dubbelhuis PF, Meijer AJ. Hepatic amino acid-dependent signaling is under the control of AMP-dependent protein kinase. FEBS Lett. 2002;521:39-42.
26. Fernández AM, Dupont J, Farrar RP, Lee S, Stannard B, LeRoith D. Muscle-specific inactivation of the IGF-I receptor induces compensatory hyperplasia in skeletal muscle. J Clin Invest. 2002; 109:347-355
27. Fong Y, Moldawer LL, Marano M, et al. Cachectin/TNF or IL-1> induces cachexia with redistribution of body proteins. Am J Physiol. 1989;256:R659-65.
28. Frame S, Balmain A. Integration of positive and negative growth signals during ras pathway activation in vivo. Curr Opin Genet Dev. 2000;10:106-113
29. Gao Z, Hwang D, Bataille F, et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kB kinase complex. J Biol Chem. 2002;277:48115-48121
30. Glund S, Deshmukh A, Long YC, et al. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes. 2007;56:1630-1637
31. Goodman MN. Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med. 1994;205:182-185
32. Hacham M, Cristal N, White RM, Segal S, Apte RN. Complementary organ expression of IL-1 vs. IL-6 and CSF-1 activities in normal and LPS-injected mice. Cytokine. 1996;8:21-31.
33. Haddad F, Adams GR. Aging sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy. J Appl Physiol. 2006;100:1188-1203
34. Haddad F, Zaldivar FP, Cooper DM, Adams GR. IL-6 induced skeletal muscle atrophy. J Appl Physiol. 2005;98:911-917
35. Hannan KM, Brandenburger Y, Jenkins A, et al. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol Cell Biol. 2003;23:8862-8877
36. Hannan KM, Hannan RD, Rothblum LI. Transcription by RNA polymerase I. Front Biosci. 1998;3:376-398
37. He J, Usui I, Ishizuka K, et al. Interleukin-1> inhibits insulin signaling with phosphorylating insulin receptor substrate-1 on serine residues in 3T3-L1 adipocytes. Mol Endocrinol. 2006;20:114-124
38. Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell. 2005;123:569-580
39. Jager J, Grémeaux T, Cormont M, LeMarchand-Brustel Y, Tanti JF. Interleukin-1A-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology. 2007;148:241-251
40. Kadi F, Schjerling P, Andersen LL, et al. The effects of heavy resistance training and detraining on satellite cells in human skeletal muscles. J Physiol. 2004;558:1005-1012
41. Kanety H, Feinstein R, Papa MZ, Hemi R, Karasik A. Tumor necrosis factor >-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem. 1995;270:23780-23784
42. Kim HJ, Higashimori T, Park SY, et al. Differential effects of interleukin-6 and-10 on skeletal muscle and liver insulin action in vivo. Diabetes. 2004;53:1060-1067
43. Kimball SR. Interaction between the AMP-activated protein ki-nase and mTOR signaling pathways. Med Sci Sports Exerc. 2006; 38(11):1958-1964
44. Krause U, Bertrand L, Hue L. Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes. Eur J Biochem. 2002;269:3751-3759
45. Lang CH, Frost RA. Sepsis-induced suppression of skeletal muscle translation initiation mediated by tumor necrosis factor >. Metabolism. 2007;56:49-57.
46. Lang CH, Frost RA, Nairn AC, MacLean DA, Vary TC. TNF-> impairs heart and skeletal muscle protein synthesis by altering translation initiation. Am J Physiol. 2002;282:E336-47.
47. Lieskovska J, Guo D, Derman E. IL-6-overexpression brings about growth impairment potentially through a GH receptor defect. Growth Horm IGF Res. 2002;12:388-398
48. Ling PR, Schwartz JH, Bistrian BR. Mechanisms of host wasting induced by administration of cytokines in rats. Am J Physiol. 1997;272:E333-9.
49. Musarò A, McCullagh K, Paul A, et al. Localized IGF-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27:195-200.
50. Nader GA, McLoughlin TJ, Esser KA. mTOR function in skeletal muscle hypertrophy: increased ribosomal RNA via cell cycle regulators. Am J Physiol. 2005;289:C1457-65.
51. Pedersen BK. IL-6 signalling in exercise and disease. Biochem Soc Trans. 2007;35:1295-1297
52. Pederson TM, Kramer DL, Rondinone CM. Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. Diabetes. 2001;50:24-31.
53. Petrella JK, Kim JS, Mayhew DL, Cross JM, Bamman MM. Potent myofiber hypertrophy during resistance training in humans is associated with satellite cell-mediated myonuclear addition: a cluster analysis. J Appl Physiol. 2008;104:1736-1742
54. Quinn LS, Haugk KL, Grabstein KH. Interleukin-15: a novel anabolic cytokine for skeletal muscle. Endocrinology. 1995;136: 3669-3672
55. Raj DS, Shah H, Shah VO, et al. Markers of inflammation, pro-teolysis, and apoptosis in ESRD. Am J Kidney Dis. 2003;42: 1212-1220
56. Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol. 2001;3:1009-1013
57. Ruderman NB, Keller C, Richard AM, et al. Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes. 2006;55:S48-54.
58. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 2002;277:42394-42398
59. Saini A, Al-Shanti N, Faulkner SH, Stewart CE. Pro-and anti-apoptotic roles for IGF-I in TNF->-induced apoptosis: a MAP kinase mediated mechanism. Growth Factors. 2008;26:239-253
60. Saini A, Al-Shanti N, Stewart CE. Waste management-cytokines, growth factors and cachexia. Cytokine Growth Factor Rev. 2006;17:475-486
61. Sawczenko A, Azooz O, Paraszczuk J, et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the j174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci U S A. 2005;102:13260-13265
62. Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med. 2006;119:e9-17.
63. Sjöholm A, Nyström T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev. 2006;22:4-10.
64. Smith MA, Moylan JS, Smith JD, Li W, Reid MB. IFN-F does not mimic the catabolic effects of TNF->. Am J Physiol Cell Physiol. 2007;293:C1947-52.
65. Spangenburg EE, Le Roith D, Ward CW, Bodine SC. A functional insulin-like growth factor receptor is not necessary for load-induced skeletal muscle hypertrophy. J Physiol. 2008;586:283-291
66. Strle K, Broussard SR, McCusker RH, et al. Proinflammatory cytokine impairment of insulin-like growth factor I-induced protein synthesis in skeletal muscle myoblasts requires ceramide. Endocrinology. 2004;145:4592-4602
67. Strle K, Broussard SR, McCusker RH, et al. C-jun N-terminal kinase mediates tumor necrosis factor-> suppression of differentiation in myoblasts. Endocrinology. 2006;147:4363-4373
68. Strle K, McCusker RH, Johnson RW, Zunich SM, Dantzer R, Kelley KW. Prototypical anti-inflammatory cytokine IL-10 prevents loss of IGF-I-induced myogenin protein expression caused by IL-1A. Am J Physiol. 2008;294:E709-18.
69. Sun H, Tu X, Liu M, Baserga R. Dual regulation of upstream binding factor 1 levels by IRS-1 and ERKs in IGF-1-receptor signaling. J Cell Physiol. 2007;212:780-786
70. Takahashi T, Fukuda K, Pan J, et al. Characterization of insulinlike growth factor-I-induced activation of the JAK/STAT pathway in rat cardiomyocytes. Circ Res. 1999;85:884-891
71. Tan JC, Rabkin R. Suppressors of cytokine signaling in health and disease. Pediatr Nephrol. 2005;20:567-575
72. Uno T, He J, Usui I, et al. Long-term interleukin-1> treatment inhibits insulin signaling via IL-6 production and SOCS3 expression in 3T3-L1 adipocytes. Horm Metab Res. 2008;40:8-12.
73. van Hall G, Steensberg A, Fischer C, et al. Interleukin-6 markedly decreases skeletal muscle protein turnover and increases non-muscle amino acid utilization in healthy individuals. J Clin Endocrinol Metab. 2008;93:2851-2858
74. Vary TC, Deiter G, Lang CH. Cytokine-triggered decreases in levels of phosphorylated eukaryotic initiation factor 4G in skeletal muscle during sepsis. Shock. 2006;26:631-636
75. Vary TC, Kimball SR. Sepsis-induced changes in protein synthesis: differential effects on fast-and slow-twitch muscles. Am J Physiol. 1992;262:C1513-9.
76. Weigert C, Hennige AM, Lehmann R, et al. Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem. 2006;281:7060-7067
77. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:818-825
78. Zong C, Chan J, Levy DE, Horvath C, Sadowski HB, Wang L. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem. 2000;275:15099-15105